Try as we might, we can’t cover all the biotech news out there! It’s summer, so the news is thinner on the ground than usual, but here’s a roundup of news that didn’t make the cut this week.
- Swedish Hansa Medical is starting a long-term study to assess the success of kidney transplantation after treatment with its drug imlifidase, which is designed to minimise rejection in these patients.
- The Italian company Menarini Ricerche has taken over sponsorship of a Phase I/II trial investigating a new treatment for acute myeloid leukemia, which was developed in collaboration with Polish biotech Selvita.
- Britannia Pharmaceuticals reported good Phase III results for its add-on Parkinson’s disease treatment, which according to the UK company reduced symptoms of shaking in people with the disease.
- Swedish Eurocine Vaccines came a step closer to the market with its nasal flu vaccine, which showed good safety results in older adults in a second Phase I/II trial.
- Astellas Pharma bought Quethera to enhance the Japanese company’s ophthalmology pipeline with the UK biotech’s novel gene therapy candidate for glaucoma.
- Rare disease specialist Therachon, based in Switzerland, has raised $60M (€52M) in mezzanine financing to help progress its treatment for achondroplasia and expand its rare disease pipeline.
- A German-US research collaboration discovered that a high rate of infection of neurons in the brain with the herpes virus could be behind conditions such as bipolar disorder and severe depression.
Images via Shutterstock